Related Experiment Video
Updated: Jun 18, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking
Megumi Yamaji1, Tomomi Nakahara2, Tomoko Nakanishi1
1Center of Biomedical Research Resources, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
Abstract:
Human papillomavirus (HPV) is a prime target for genome-editing therapy as its E6 and E7 oncogenes are crucial for cancer development and maintenance. A key challenge in CRISPR/Cas9 therapy is the off-target effects. This study utilized a double-nicking technique to introduce DNA breaks in the E6 and E7 regions of HPV16. From 146 gRNA candidates, 16 double-nicking pairs were selected. Multiple combinations of double-nicking (DN)-gRNA pairs were delivered to HPV16-positive cells via lentiviruses, followed by Cas9 nickase (Cas9n) expression. Combinations of 3-4 DN-gRNA pairs effectively killed HPV16-positive cells while sparing HPV-negative cells. Off-target effects were reduced by nearly three orders of magnitude. An "all-in-one" adenovirus (AdV) system expressing four gRNA pairs and Cas9n showed promise in inhibiting tumor growth in HPV16-positive cancer models, demonstrating its potential as a safe and effective treatment for HPV-induced tumors.
Insights
This study used a double-nicking CRISPR/Cas9 technique to target human papillomavirus (HPV) oncogenes, significantly reducing off-target effects for safer cancer therapy.
Area of Science:
- Genomic Medicine
- Oncology
- Viral Oncology
Background:
- Human papillomavirus (HPV) oncoproteins E6 and E7 are critical for cervical cancer development.
- CRISPR/Cas9 genome editing offers a potential therapeutic strategy against HPV-induced cancers.
- Minimizing off-target effects is essential for the clinical safety of CRISPR/Cas9 therapies.
Purpose of the Study:
- To develop a precise genome-editing strategy targeting HPV16 E6 and E7 oncogenes.
- To assess the efficacy and specificity of a double-nicking CRISPR/Cas9 approach.
- To evaluate the therapeutic potential of an adenovirus-delivered system for HPV-positive cancers.
Main Methods:
- Designed and selected double-nicking (DN)-gRNA pairs targeting HPV16 E6/E7 oncogenes.
- Delivered DN-gRNA pairs and Cas9 nickase (Cas9n) to HPV16-positive cells using lentiviral vectors.
- Utilized an all-in-one adenovirus (AdV) system for in vivo delivery of gRNAs and Cas9n.
- Quantified cell killing, off-target effects, and tumor growth inhibition in preclinical models.
Main Results:
- Multiple DN-gRNA pair combinations effectively eliminated HPV16-positive cancer cells while sparing normal cells.
- Off-target mutations were reduced by nearly three orders of magnitude compared to standard CRISPR/Cas9.
- The AdV-based system demonstrated significant inhibition of tumor growth in HPV16-positive cancer models.
- The approach showed high specificity for HPV-infected cells.
Conclusions:
- The double-nicking CRISPR/Cas9 technique offers enhanced safety and specificity for targeting HPV oncogenes.
- Adenovirus-mediated delivery of this system presents a promising therapeutic strategy for HPV-induced malignancies.
- This genome-editing approach holds potential for developing safer and more effective treatments for HPV-related cancers.
Related Concept Videos
Viral Mutations
Retroviruses
Leaky Scanning
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Viruses with RNA Genomes

